Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452404 | PMC |
http://dx.doi.org/10.1097/EDE.0000000000000305 | DOI Listing |
PLOS Glob Public Health
January 2025
CEPED, IRD-Université de Paris, ERL INSERM SAGESUD, Paris, France.
Bangladesh completed a primary series of COVID-19 vaccinations for about 86 individuals per 100 population as of 5 July 2023. However, ensuring higher coverage in vulnerable areas is challenging. We report on the COVID-19 vaccine uptake and associated factors among adults in two vulnerable areas in Bangladesh.
View Article and Find Full Text PDFPLoS One
January 2025
Institute of Cognitive Sciences and Technologies, National Research Council, Rome, Italy.
This study examines whether the detrimental effects of the COVID-19 pandemic on the affectivity of the population extend one year after the outbreak. In an online-mobile session, participants completed surveys (i.e.
View Article and Find Full Text PDFPLoS One
January 2025
Departement of Epidemiology, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia.
Introduction: Ovarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies.
View Article and Find Full Text PDFPLoS One
January 2025
Department of General Practice, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Background: The rising prevalence of depression among cancer patients is alarming. This study examines the relationship between the Oxidative Balance Score (OBS)-a composite measure of dietary and lifestyle factors-and depression, including specific depressive symptoms in this population.
Methods: Data were analyzed from 3,280 adult cancer patients collected in NHANES from 2005-2020.
Prim Care Companion CNS Disord
January 2025
Eisai Inc, Nutley, New Jersey.
Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!